Articles by Ankit Singhania

Based in India, Ankit is a financial content writer and stock market analyst. He has worked for almost a decade on several financial projects related to the stock market news, fundamental research and technical analysis for several websites. He obtained his Masters Degree In finance (MS – finance) from ICFAI. Currently, he serves as a financial consultant and technical analyst at Tradersinsights.com.

PHAS Stock Zooms 440%: What Next for PhaseBio Pharmaceuticals?

Apr 10 Ankit Singhania

PHAS stock has been on fire over the past month, gaining over 440% during this period. Today PhaseBio Pharmaceuticals (NASDAQ:PHAS) is valued at more than $350 million. This week, PHAS stock leaped 32.5% after the ... [Read]

DERM Stock Doubles in a Month on Lebrikizumab’s Buzz

Apr 9 Ankit Singhania

DERM stock investors are getting excited and for good reason too. Dermira (NASDAQ:DERM) released positive progress for a key drug candidate, lebrikizumab, back in mid-March and shares have been climbing since. Since March 15th, DERM stock ... [Read]

CHK Stock: Chesapeake Energy Keeps Up with Crude Oil Prices

Apr 8 Ankit Singhania

All seems well right now for CHK stock, which, last year, plunged dangerously. To be sure, Chesapeake Energy Corporation (NYSE:CHK) shares lost 47% of their value when the price of crude oil tanked. However, CHK ... [Read]

ZYNE Stock Zooms Over 50% This Week, What Next for Zynerba?

Apr 5 Ankit Singhania

ZYNE stock continued to gain momentum in Friday’s session and was recently moving up by 10.36% to $8.53 USD, extending its winning streak for the fourth straight session. Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are up ... [Read]

ACHN Stock Climbs After Achillion Pharmaceuticals’ Trial Fills Up

Apr 4 Ankit Singhania

ACHN stock is one of the top performing biotech stocks so far in 2019. Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) are up over 115% since early January amid several key clinical updates. In Wednesday’s session, Achillion ... [Read]

Biotech Stocks on Radar: FibroGen, Heron Therapeutics, GW, and Assembly

Apr 3 Ankit Singhania

We’ve shortlisted four major biotech stocks with upcoming news in April related to FDA decisions. Where will the news take GW Pharmaceuticals (NASDAQ:GWPH), FibroGen (NASDAQ:FGEN), Heron Therapeutics (NASDAQ:HRTX), and Assembly Biosciences (NASDAQ:ASMB)? Biotech Stocks: GW Pharmaceuticals ... [Read]